How are GMED strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GMED strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 32.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$325.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a GMED strangle?

The breakeven for the GMED strangle priced on this page is roughly $69.25 and $83.25 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GMED market-implied 1-standard-deviation expected move is approximately 9.40%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current GMED implied volatility affect this strangle?

GMED ATM IV is at 32.80% with IV rank near 16.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

GMED Strangle Strategy

GMED (Globus Medical, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED (Globus Medical, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $10.19B, a trailing P/E of 17.43, a beta of 1.00 versus the broader market, a 52-week range of 51.79-101.4, average daily share volume of 1.2M, a public-listing history dating back to 2012, approximately 5K full-time employees. These structural characteristics shape how GMED stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.00 places GMED roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on GMED?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current GMED snapshot

As of May 15, 2026, spot at $76.44, ATM IV 32.80%, IV rank 16.68%, expected move 9.40%. The strangle on GMED below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on GMED specifically: GMED IV at 32.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a GMED strangle, with a market-implied 1-standard-deviation move of approximately 9.40% (roughly $7.19 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GMED expiries trade a higher absolute premium for lower per-day decay. Position sizing on GMED should anchor to the underlying notional of $76.44 per share and to the trader's directional view on GMED stock.

GMED strangle setup

The GMED strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GMED near $76.44, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GMED chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GMED shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$80.00	$1.65
Buy 1	Put	$72.50	$1.60

GMED strangle risk and reward

Net Premium / Debit: -$325.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$325.00
Breakeven(s): $69.25, $83.25
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

GMED strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on GMED. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$6,924.00
$16.91	-77.9%	+$5,233.98
$33.81	-55.8%	+$3,543.96
$50.71	-33.7%	+$1,853.94
$67.61	-11.6%	+$163.92
$84.51	+10.6%	+$126.10
$101.41	+32.7%	+$1,816.12
$118.31	+54.8%	+$3,506.14
$135.21	+76.9%	+$5,196.16
$152.11	+99.0%	+$6,886.18

When traders use strangle on GMED

Strangles on GMED are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GMED chain.

GMED thesis for this strangle

The market-implied 1-standard-deviation range for GMED extends from approximately $69.25 on the downside to $83.63 on the upside. A GMED long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GMED IV rank near 16.68% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on GMED at 32.80%. As a Healthcare name, GMED options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GMED-specific events.

GMED strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GMED positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GMED alongside the broader basket even when GMED-specific fundamentals are unchanged. Always rebuild the position from current GMED chain quotes before placing a trade.

Frequently asked questions

What is a strangle on GMED?: A strangle on GMED is the strangle strategy applied to GMED (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GMED stock trading near $76.44, the strikes shown on this page are snapped to the nearest listed GMED chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are GMED strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GMED strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 32.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$325.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a GMED strangle?: The breakeven for the GMED strangle priced on this page is roughly $69.25 and $83.25 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GMED market-implied 1-standard-deviation expected move is approximately 9.40%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on GMED?: Strangles on GMED are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GMED chain.
How does current GMED implied volatility affect this strangle?: GMED ATM IV is at 32.80% with IV rank near 16.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.